Lymphoid Malignancies clinical trials at UCLA

1 research study open to eligible people

Showing trials for

  • OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies

    open to eligible people ages 12-95

    This is an open-label, Phase 1/2 study designed to characterize the safety, tolerability, Pharmacokinetics(PK), and preliminary antitumor activity of AVM0703 administered as a single intravenous (IV) infusion to patients with lymphoid malignancies.

    Los Angeles, California and other locations

Our lead scientists for Lymphoid Malignancies research studies include .

Last updated: